Table 6 Univariable and multivariable logistic regression for the risk of graft dysfunction at one year from kidney transplantation
Variables | Univariable analysis | Multivariable analysisa | ||||
|---|---|---|---|---|---|---|
-2log likelihood: 69.886 | ||||||
OR | 95% CI | P | AOR | 95% CI | P | |
Baseline | ||||||
Full-length CTLA4 | 2.033 | 0.643-6.428 | 0.227 | — | — | — |
Soluble CTLA4 | 2.610 | 0.882-7.729 | 0.083 | — | — | — |
FOXP3 | 3.111 | 0.869-11.133 | 0.081 | — | — | — |
At 15 days | ||||||
Full-length CTLA4 | 2.462 | 0.897-6.752 | 0.080 | — | — | — |
Soluble CTLA4 | 2.628 | 1.015-6.800 | 0.046 | 3.683 | 1.145-11.845 | 0.029 |
FOXP3 | 2.301 | 0.836-6.331 | 0.107 | — | — | — |
At 60 days | ||||||
Full-length CTLA4 | 1.962 | 0.519-7.412 | 0.320 | — | — | — |
Soluble CTLA4 | 1.726 | 0.559-5.328 | 0.343 | — | — | — |
FOXP3 | 1.132 | 0.376-3.402 | 0.826 | — | — | — |
At one year | ||||||
Full-length CTLA4 | 1.356 | 0.163-11.318 | 0.778 | — | — | — |
Soluble CTLA4 | 2.574 | 0.302-21.913 | 0.387 | — | — | — |
FOXP3 | 4.381 | 0.261-73.437 | 0.304 | — | — | — |
Recipient age | 1.072 | 1.026-1.121 | 0.002 | — | — | — |
Recipient gender | 1.095 | 0.417-2.873 | 0.854 | — | — | — |
Donor age | 1.094 | 1.049-1.141 | 0.000 | 1.084 | 1.033-1.137 | 0.001 |
Donor gender | 0.395 | 0.150-1.036 | 0.059 | — | — | — |
Type of donor | 1.085 | 0.172-6.852 | 0.931 | — | — | — |
Previous transplantation | 3.043 | 0.326-28.445 | 0.329 | — | — | — |
HLA mismatch | 1.106 | 0.787-1.554 | 0.563 | — | — | — |
cRF (first class) | 0.421 | 0.174-1.019 | 0.055 | — | — | — |
cRF (second class) | 0.552 | 0.220-1.387 | 0.206 | — | — | — |
CIT | 1.000 | 0.999-1.002 | 0.547 | — | — | — |
WIT | 1.004 | 0.971-1.038 | 0.820 | — | — | — |
Type of renal replacement therapy | 1.796 | 0.586-5.502 | 0.305 | — | — | — |
Dialysis time | 1.001 | 0.989-1.001 | 0.889 | — | — | — |
CMV reactivation | 1.230 | 0.449-3.371 | 0.688 | — | — | — |
Type of inductionb | 0.258 | 0.047-1.415 | 0.119 | — | — | — |
CNI Tacrolimus vs. Cyclosporine | 0.500 | 0.143-1.744 | 0.277 | — | — | — |
Use of everolimus | 1.302 | 0.351-4.831 | 0.693 | — | — | — |
Immunosuppression change | 3.111 | 0.929-10.422 | 0.066 | — | — | — |
DGF | 2.534 | 0.965-6.658 | 0.059 | — | — | — |
Development of DSA | 1.579 | 0.531-4.699 | 0.412 | — | — | — |
Proteinuria at one year (mg/l) | 1.002 | 0.998-1.005 | 0.344 | |||